These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 21282564)

  • 1. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
    Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
    J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
    Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
    J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
    Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
    Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
    Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
    Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
    Chen LC; Tu SH; Huang CS; Chen CS; Ho CT; Lin HW; Lee CH; Chang HW; Chang CH; Wu CH; Lee WS; Ho YS
    Breast Cancer Res Treat; 2012 Aug; 134(3):989-1004. PubMed ID: 22434522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
    Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
    Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
    Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
    Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
    Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
    Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
    Goc A; Al-Husein B; Katsanevas K; Steinbach A; Lou U; Sabbineni H; DeRemer DL; Somanath PR
    Oncotarget; 2014 Feb; 5(3):775-87. PubMed ID: 24519956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.
    McKinley ET; Liu H; McDonald WH; Luo W; Zhao P; Coffey RJ; Hanks SK; Manning HC
    PLoS One; 2013; 8(11):e80207. PubMed ID: 24260357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
    Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
    Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.